The latest clinical breakthroughs, practice management updates, and national advocacy alerts directly from the American Academy of Ophthalmology.
First-Year Visual Acuity Outcomes in the United Kingdom of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration
Aflibercept has the potential advantage of reducing capacity problems by allowing 2 monthly visits for patients with neovascular macular degeneration (nAMD) compared with monthly pro re nata regimens that are the most commonly used in the United Kingdom. This study aimed to report the visual outcomes achieved in routine clinical practice using the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) protocol at 1 year and compare with trials data and other real-world reports.
We extend our deepest gratitude to our Platinum, Gold, and Silver partners. Your generous support fuels our mission to advance medical education, advocate for patient safety, and foster breakthrough innovations across West Virginia.